{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053974","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.292369+00:00","generated_at":"2026-06-02T18:41:36.864919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cogent Biosciences Q1 net loss $58.3M; cash $435.7M funds operations into 2027","bullets":["Cash and marketable securities $435.7M as of Mar 31, 2024, up from $273.2M year-end 2023.","Net loss $58.3M in Q1 2024 vs $38.6M in Q1 2023; R&D expenses $52.7M (up 46% YoY).","Enrollment on track in APEX, PEAK (end 2024) and SUMMIT (Q2 2025); topline results expected in 2025.","Completed oversubscribed private placement yielding $213.4M net proceeds.","Selected 100 mg once-daily dose for SUMMIT Part 2 based on 51% mean TSS improvement at week 12."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053974","json":"https://secwatch.observer/filing/0000950170-24-053974.json","markdown":"https://secwatch.observer/filing/0000950170-24-053974.md","text":"https://secwatch.observer/filing/0000950170-24-053974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024053974/0000950170-24-053974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024053974/cogt-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:41:36.864919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9887d8e50213c589beceb310e8a458cc3ae86596","claim":"Cogent Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $58.3 million.","evidence_excerpt":"Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024053974/0000950170-24-053974-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $58.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}